Your session is about to expire
← Back to Search
Hypofractionated Radiotherapy for Prostate Cancer (HEAT Trial)
HEAT Trial Summary
This trial will compare a new, more intensive treatment for prostate cancer to the standard treatment. The new treatment will be given in fewer, but larger doses, over a shorter period of time.
HEAT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHEAT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.HEAT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My prostate cancer was confirmed through a tissue examination.My prostate cancer has a low to medium grade.My PSA level is below 20 ng/ml, measured within the last 3 months.I can have gold markers placed in my prostate.I can carry out all my usual activities without help.I have not had my prostate completely removed or frozen.I have received 4-6 months of hormone therapy for my cancer.I am willing to complete forms about my quality of life and mental health.I have not had chemotherapy in the last 5 years.I have used hormone therapy for prostate cancer for more than 2 months.I cannot have gold markers placed in my prostate.My prostate is larger than 80 cc.I am between 35 and 85 years old.My cancer has spread to nearby lymph nodes or other parts of my body.I have some trouble doing my daily activities due to my health.I have had my entire prostate removed.I was diagnosed with cancer that has spread within the last 5 years.My cancer is in an early stage and has not spread to distant parts of my body.I do not have prostate cancer.My cancer is at a stage where it has grown significantly but not spread to distant organs.I am not willing to complete life quality or mental health surveys.I am younger than 35 or older than 85 years old.My prostate is 80 cc or smaller.I have had radiation therapy to my prostate or lower pelvis.My PSA level is above 20 ng/ml, measured within the last 3 months.
- Group 1: Extended Hypofractionation Radiotherapy (EHRT) Group
- Group 2: Accelerated Hypofractionation Radiotherapy (AHRT) Group
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the basic requirements to take part in this clinical trial?
"This clinical trial is looking for 456 participants that are between 35 and 85 years old and have prostate cancer. Other inclusion criteria are as follows: must have a Gleason score of ≤ 6, a PSA level of ≤ 10, and < 50% positive biopsy cores; must have a Prostate-Specific Antigen (PSA) level < 20 ng/ml that was obtained no more than 3 months prior to enrollment; must have histologically proven prostate adenocarcinoma; must have a Gleason score of 2-7 that has been reviewed by the reference lab at UM; must have had a biopsy within"
Are patients still being accepted into the trial program?
"That is correct. The listed information on clinicaltrials.gov affirms that this research is actively seeking participants. This trial was first posted on April 4th, 2013 and was most recently updated on December 1st, 2021. 456 individuals are needed to be enrolled from a single site."
Could you please share how many people are currently enrolled in this research?
"The clinical trial is actively recruiting patients, as noted on clinicaltrials.gov. The original posting date was April 4th, 2013, and the most recent update was December 1st, 2021. They are looking for 456 patients from 1 location."
Does this research include patients that are above the age of 50?
"The age bracket for this particular trial is 35 to 85. There are 77 clinical trials for people who are under 18 and 1344 for people who are over 65."
Share this study with friends
Copy Link
Messenger